143
3. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al.
Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev.
2009;30(4):293–342.
4. Rousselle C, Ormsby JN, Schaefer B, Lampen A, Platzek T, Hirsch-Ernst K, et al. Meeting
report: international workshop on endocrine disruptors: exposure and potential impact on consumers health. Regul Toxicol Pharmacol. 2013;65(1):7–11.
5. Casals-Casas C, Desvergne B. Endocrine disruptors: from endocrine to metabolic disruption.
Annu Rev Physiol. 2011;73:135–62.
6. Colborn T, Vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals
in wildlife and humans. Environ Health Perspect. 1993;101(5):378–84.
7. De Coster S, Van Larebeke N. Endocrine-disrupting chemicals: associated disorders and
mechanisms of action. J Environ Public Health. 2012;2012:713696.
8. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC
Public Health. 2009;9(1):88.
9. Keith SW, Redden DT, Katzmarzyk PT, Boggiano MM, Hanlon EC, Benca RM, et al. Putative
contributors to the secular increase in obesity: exploring the roads less traveled. Int J Obes
(Lond). 2006;30(11):1585–94.
10. Hamilton MT, Hamilton DG, Zderic TW. Role of low energy expenditure and sitting in
obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes. 2007;
56(11):2655–67.
11. Smith MS. H. Maurice Goodman: Basic medical endocrinology. 4th ed. Cambridge: Academic
Press; 2009.
12. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;
89(6):2548–56.
13. Newbold RR, Padilla-Banks E, Jefferson WN. Environmental estrogens and obesity. Mol Cell
Endocrinol. 2009;304(1-2):84–9.
14. Howdeshell KL, Hotchkiss AK, Thayer KA. Vandenbergh JG, vom Saal FS. Exposure to
bisphenol A advances puberty Nature. 1999;401(6755):763–4.
15. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN. Developmental exposure to estrogenic compounds and obesity. Birth Defects Res A Clin Mol Teratol. 2005;73(7):478–80.
16. Grün F, Blumberg B. Endocrine disrupters as obesogens. Mol Cell Endocrinol. 2009;
304(1-2):19–29.
17. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med.
2004;10(4):355–61.
18. Hurst CH, Waxman DJ. Activation of PPARα and PPARγ by environmental phthalate monoesters. Toxicol Sci. 2003;74(2):297–308.
19. Rubin BS, Soto AM. Bisphenol A: perinatal exposure and body weight. Mol Cell Endocrinol.
2009;304(1-2):55–62.
20. Gore AC. Endocrine-disrupting chemicals. JAMA Intern Med. 2016;176(11):1705–6.
21. Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and
the diabetes epidemic. Diabetes. 2011;60(7):1838–48.
22. Nadal A, Fuentes E, Ripoll C, Villar-Pazos S, Castellano-Muñoz M, Soriano S, et al.
Extranuclear-initiated estrogenic actions of endocrine disrupting chemicals: Is there toxicology beyond paracelsus? J Steroid Biochem Mol Biol. 2018;176:16–22.
23. Longnecker MP, Daniels JL. Environmental contaminants as etiologic factors for diabetes.
Environ Health Perspect. 2001;109(suppl 6):871–6.
24. Yang O, Kim HL, Weon JI, Seo YR. Endocrine-disrupting chemicals: review of toxicological
mechanisms using molecular pathway analysis. J Cancer Prev. 2015;20(1):12–24.
25. Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within
us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14(5):273–87.
26. Patterson AD, Turnbaugh PJ. Microbial determinants of biochemical individuality and their
impact on toxicology and pharmacology. Cell Metab. 2014;20(5):761–8.
9 Alteration of Gut Microbiota in EDCs-Induced Metabolic Disorders
3. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al.
Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev.
2009;30(4):293–342.
4. Rousselle C, Ormsby JN, Schaefer B, Lampen A, Platzek T, Hirsch-Ernst K, et al. Meeting
report: international workshop on endocrine disruptors: exposure and potential impact on consumers health. Regul Toxicol Pharmacol. 2013;65(1):7–11.
5. Casals-Casas C, Desvergne B. Endocrine disruptors: from endocrine to metabolic disruption.
Annu Rev Physiol. 2011;73:135–62.
6. Colborn T, Vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals
in wildlife and humans. Environ Health Perspect. 1993;101(5):378–84.
7. De Coster S, Van Larebeke N. Endocrine-disrupting chemicals: associated disorders and
mechanisms of action. J Environ Public Health. 2012;2012:713696.
8. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC
Public Health. 2009;9(1):88.
9. Keith SW, Redden DT, Katzmarzyk PT, Boggiano MM, Hanlon EC, Benca RM, et al. Putative
contributors to the secular increase in obesity: exploring the roads less traveled. Int J Obes
(Lond). 2006;30(11):1585–94.
10. Hamilton MT, Hamilton DG, Zderic TW. Role of low energy expenditure and sitting in
obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes. 2007;
56(11):2655–67.
11. Smith MS. H. Maurice Goodman: Basic medical endocrinology. 4th ed. Cambridge: Academic
Press; 2009.
12. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;
89(6):2548–56.
13. Newbold RR, Padilla-Banks E, Jefferson WN. Environmental estrogens and obesity. Mol Cell
Endocrinol. 2009;304(1-2):84–9.
14. Howdeshell KL, Hotchkiss AK, Thayer KA. Vandenbergh JG, vom Saal FS. Exposure to
bisphenol A advances puberty Nature. 1999;401(6755):763–4.
15. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN. Developmental exposure to estrogenic compounds and obesity. Birth Defects Res A Clin Mol Teratol. 2005;73(7):478–80.
16. Grün F, Blumberg B. Endocrine disrupters as obesogens. Mol Cell Endocrinol. 2009;
304(1-2):19–29.
17. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med.
2004;10(4):355–61.
18. Hurst CH, Waxman DJ. Activation of PPARα and PPARγ by environmental phthalate monoesters. Toxicol Sci. 2003;74(2):297–308.
19. Rubin BS, Soto AM. Bisphenol A: perinatal exposure and body weight. Mol Cell Endocrinol.
2009;304(1-2):55–62.
20. Gore AC. Endocrine-disrupting chemicals. JAMA Intern Med. 2016;176(11):1705–6.
21. Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and
the diabetes epidemic. Diabetes. 2011;60(7):1838–48.
22. Nadal A, Fuentes E, Ripoll C, Villar-Pazos S, Castellano-Muñoz M, Soriano S, et al.
Extranuclear-initiated estrogenic actions of endocrine disrupting chemicals: Is there toxicology beyond paracelsus? J Steroid Biochem Mol Biol. 2018;176:16–22.
23. Longnecker MP, Daniels JL. Environmental contaminants as etiologic factors for diabetes.
Environ Health Perspect. 2001;109(suppl 6):871–6.
24. Yang O, Kim HL, Weon JI, Seo YR. Endocrine-disrupting chemicals: review of toxicological
mechanisms using molecular pathway analysis. J Cancer Prev. 2015;20(1):12–24.
25. Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within
us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14(5):273–87.
26. Patterson AD, Turnbaugh PJ. Microbial determinants of biochemical individuality and their
impact on toxicology and pharmacology. Cell Metab. 2014;20(5):761–8.
9 Alteration of Gut Microbiota in EDCs-Induced Metabolic Disorders